101
Views
19
CrossRef citations to date
0
Altmetric
Original Research

Design and validation of standardized clinical and functional remission criteria in schizophrenia

, , , &
Pages 167-181 | Published online: 28 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Marcelo Valencia, Ana Fresán, Yoram Barak, Francisco Juárez, Raul Escamilla & Ricardo Saracco. (2015) Predicting functional remission in patients with schizophrenia: a cross-sectional study of symptomatic remission, psychosocial remission, functioning, and clinical outcome. Neuropsychiatric Disease and Treatment 11, pages 2339-2348.
Read now
Alkomiet Hasan, Peter Falkai, Thomas Wobrock, Jeffrey Lieberman, Birte Glenthøj, Wagner F. Gattaz, Florence Thibaut & Hans-Jürgen Möller. (2015) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. The World Journal of Biological Psychiatry 16:3, pages 142-170.
Read now
Bandar AlAqeel. (2014) Proposed criteria for schizophrenia remission. Neuropsychiatric Disease and Treatment 10, pages 619-623.
Read now
Georg Juckel, Andrea de Bartolomeis, Philip Gorwood, Sergey Mosolov, Luca Pani, Alessandro Rossi & Julio Sanjuan. (2014) Towards a framework for treatment effectiveness in schizophrenia. Neuropsychiatric Disease and Treatment 10, pages 1867-1878.
Read now

Articles from other publishers (15)

Egor Chumakov, Mariia Dorofeikova, Kristina Tsyrenova & Nataliia Petrova. (2022) A Cross-Sectional Study on Associations Between BDNF, CRP, IL-6 and Clinical Symptoms, Cognitive and Personal Performance in Patients With Paranoid Schizophrenia. Frontiers in Psychiatry 13.
Crossref
Emine KARAKAYALI, Erdoğan KOCAMAZ, Şüheda ALPAY, Tuna ÖNAL, Mustafa ÖZTATLICI, Rabia DURUŞMA, Hasan Fehmi ÖZEL, Mesut METE, Necip KUTLU & Mehmet İbrahim TUĞLU. (2022) Effect of Probiotics on the Traumatic Brain Injury. Forbes Journal of Medicine 3:1, pages 59-67.
Crossref
Sergey N. Mosolov & Polina A. Yaltonskaya. (2022) Primary and Secondary Negative Symptoms in Schizophrenia. Frontiers in Psychiatry 12.
Crossref
Manuel Rojas, Maite Barrios, Juana Gómez-Benito, Nadezhda Mikheenkova & Sergey Mosolov. (2021) Functioning Problems in Persons with Schizophrenia in the Russian Context. International Journal of Environmental Research and Public Health 18:19, pages 10276.
Crossref
. (2020) Remission structure in schizoaffective disorder. Psychiatry Neurology and Medical Psychology:14.
Crossref
V.V. Kravtsov, I.A. Filippov, E.E. Vaiman, N.A. Shnayder & R.F. Nasyrova. (2020) Pharmacogenetic aspects of the dopaminergic system in clozapine pharmacodynamics. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 120:7, pages 134.
Crossref
V.V. Kravtsov, I.A. Filippov, E.E. Vaiman, N.A. Shnayder & R.F. Nasyrova. (2020) Pharmacogenetic aspects of the dopaminergic system in clozapine pharmacodynamics. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 120:7, pages 134.
Crossref
S.K. Zyryanov, I.N. Dyakov, A.A. Juperin, D.A. Egorova & E.S. Mosolova. (2020) The pharmacoeconomic efficacy of lurasidone in the treatment of schizophrenia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 120:6, pages 82.
Crossref
Philip Gorwood, Sophie Bouju, Cécile Deal, Charlotte Gary, Catherine Delva, Sylvie Lancrenon & Pierre-Michel Llorca. (2019) Predictive factors of functional remission in patients with early to mid-stage schizophrenia treated by long acting antipsychotics and the specific role of clinical remission. Psychiatry Research 281, pages 112560.
Crossref
Laura Nuño, Georgina Guilera, Michaela Coenen, Emilio Rojo, Juana Gómez-Benito & Maite Barrios. (2019) Functioning in schizophrenia from the perspective of psychologists: A worldwide study. PLOS ONE 14:6, pages e0217936.
Crossref
S. N. Mosolov, A. V. Malyutin & A. A. Pikalov. (2019) Effect of Lurasidone on symptoms of schizophrenia in five-factor dimensional model: pooled analysis of two short-term, randomized, double-blind, placebo-controlled studies in patients from Russia and Ukraine. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 119:12, pages 29.
Crossref
I. N. Dyakov & S. K. Zyryanov. (2019) Clinical and economic efficiency of treatment with cariprazine in schizophrenia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 119:7, pages 69.
Crossref
Philip Gorwood, Jasmina Mallet & Sylvie Lancrenon. (2018) Functional remission in schizophrenia: A FROGS-based definition and its convergent validity. Psychiatry Research 268, pages 94-101.
Crossref
Mariia Dorofeikova, Nikolay Neznanov & Nataliia Petrova. (2018) Cognitive deficit in patients with paranoid schizophrenia: Its clinical and laboratory correlates. Psychiatry Research 262, pages 542-548.
Crossref
Marta Francesconi, Amedeo Minichino, Ricardo E. Carrión, Roberto Delle Chiaie, Arturo Bevilacqua, Maurizio Parisi, Santo Rullo, Francesco Saverio Bersani, Massimo Biondi & Kristin Cadenhead. (2016) Theory of Mind as a mediator variable between neurocognition and functioning in young individuals in treatment with secondary services for non-psychotic disorders. Psychiatry Research 246, pages 415-420.
Crossref